

Correction to the Article “Pediatric Sarcopenia: What do We Know?”

Errata ao Artigo “Sarcopenia Pediátrica: O que Sabemos?”

Following publication of the [original article](#), the authors identified errors in the content. The corrected text is presented below. The original article has also been corrected.

Após a publicação do [artigo original](#), os autores identificaram erros no conteúdo. O texto corrigido é apresentado abaixo. O artigo original também foi corrigido.

On page 801, in the fifth paragraph of the left column, a reference has been added, and the subsequent references have been renumbered. Thus, where it reads (in red):

“Although initially focused on the elderly, sarcopenia has emerged as a growing concern among pediatric populations, particularly in children with chronic diseases. Recently, some studies have suggested that it may also be present in asymptomatic children.¹⁷”

It should read (in bold):

“Although initially focused on the elderly, sarcopenia has emerged as a growing concern among pediatric populations, particularly in children with chronic diseases. Recently, some studies have suggested that it may also be present in asymptomatic children.¹⁸”

On page 805, in the second paragraph of the ‘**FUTURE PERSPECTIVES**’ section, the last sentence has been removed (in red). Thus, where it reads:

“Due to the multifactorial nature of sarcopenia, there is an urgent need to develop validated biomarker panels for clinical use in both children and adults. **Currently, inflammatory markers like TNF-alpha and IL-6 and others like testosterone, GH, creatinine, and carnitine are used.**⁶⁵”

It should read:

“Due to the multifactorial nature of sarcopenia, there is an urgent need to develop validated biomarker panels for clinical use in both children and adults.”

On page 805, in the third paragraph of the ‘**FUTURE PERSPECTIVES**’ section, where it reads:

Genomic studies have identified certain sequences linked to an increased risk of sarcopenia, such as the *rs34415150* variant of *HLA-DQA1*, *rs143384* of *GDF5*, and *rs62102286* of *DYM*.⁶⁶ Additionally, in sarcopenic patients, genes like *MT1X* and *ARHGAP36* have shown higher diagnostic precision compared to *FAM171A1*, *GPCPD1*, *ZNF415*, and *RXRG*, indicating their potential as predictive markers for early screening.⁶⁷ Circulating microRNAs (e.g., microRNA-1, microRNA-29a, microRNA-29b) have also been observed in patients with reduced physical performance.⁶⁸”

It should read (in bold):

Genomic studies have identified certain sequences linked to an increased risk of sarcopenia **in older men and women**, such as the *rs34415150* variant of *HLA-DQA1*, *rs143384* of *GDF5*, and *rs62102286* of *DYM*.⁶⁷ Additionally, in sarcopenic patients, genes like *MT1X* and *ARHGAP36* have shown higher diagnostic precision compared to *FAM171A1*, *GPCPD1*, *ZNF415*, and *RXRG*, indicating their potential as predictive markers for early screening.⁶⁸ Circulating microRNAs (e.g., microRNA-1, microRNA-29a, microRNA-29b) have also been observed in **adult** patients with reduced physical performance.⁶⁹”

In the ‘**REFERENCES**’ section, all references following reference 18 have been renumbered.

Thus, where it reads:

19. Costello PM, Rowleson A, Astaman NA, Anthony FE, Sayer AA, Cooper C, et al. Peri-implantation and late gestation maternal undernutrition differentially affect fetal sheep skeletal muscle development. *J Physiol.* 2008;586:2371-9.
20. Chomtho S, Wells JC, Williams JE, Lucas A, Fewtrell MS. Associations between birth weight and later body composition: evidence from the 4-component model. *Am J Clin Nutr.* 2008;88:1040-8.
21. Bielemann RM, Gigante DP, Horta BL. Birth weight, intrauterine growth restriction and nutritional status in childhood in relation to grip strength in adults: from the 1982 Pelotas (Brazil) birth cohort. *Nutrition.* 2016;32:228-35.
22. Dodds R, Denison HJ, Ntani G, Cooper R, Cooper C, Sayer AA, et al. Birth weight and muscle strength: a systematic review and meta-analysis. *J Nutr Health Aging.* 2012;16:609-15.
23. Narici MV, de Boer MD. Disuse of the musculo-skeletal system in space and on earth. *Eur J Appl Physiol.* 2011;111:403-20.
24. Jung HN, Jung CH, Hwang YC. Sarcopenia in youth. *Metabolism.* 2023;144:155557.

25. Benson AC, Torode ME, Fiatarone Singh MA. Muscular strength and cardiorespiratory fitness is associated with higher insulin sensitivity in children and adolescents. *Int J Pediatr Obes.* 2006;1:222-31.
26. Steene-Johannessen J, Anderssen SA, Kolle E, Andersen LB. Low muscle fitness is associated with metabolic risk in youth. *Med Sci Sports Exerc.* 2009;41:1361.
27. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic syndrome and sarcopenia. *Nutrients.* 2021;13:3519.
28. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. *Nutrients.* 2020;12:2401.
29. Phillips CM. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. *Ann N Y Acad Sci.* 2017;1391:85-100.
30. Rezende IF, Conceição-Machado ME, Souza VS, Santos EM dos, Silva LR. Sarcopenia in children and adolescents with chronic liver disease. *J Pediatr.* 2020;96:439-46.
31. Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. *Trends Endocrinol Metab.* 2016;27:335-47.
32. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* 2010;39:412-23.
33. Rubio-Arias JA, Rodríguez-Fernández R, Andreu L, Martínez-Aranda LM, Martínez-Rodríguez A, Ramos-Campo DJ. Effect of sleep quality on the prevalence of sarcopenia in older adults: a systematic review with meta-analysis. *J Clin Med.* 2019;8:2156.
34. Liu C, Cheung W, Li J, Chow SK, Yu J, Wong SH, et al. Understanding the gut microbiota and sarcopenia: a systematic review. *J Cachexia Sarcopenia Muscle.* 2021;12:1393-407.
35. Uptodate Free. Measurement of growth in children. 2024. [cited 31 May 2024]. Available from: <https://pro.uptodatefree.ir/Show/5356>.
36. Beunen GP, Rogol AD, Malina RM. Indicators of biological maturation and secular changes in biological maturation. *Food Nutr Bull.* 2006;27:S244-56.
37. Rogol AD. Growth, body composition and hormonal axes in children and adolescents. *J Endocrinol Invest.* 2003;26:855-60.
38. Narchi H, Alblooshi A, Altunajji M, Alali N, Alshehhi L, Alshehhi H, et al. Prevalence of thinness and its effect on height velocity in schoolchildren. *BMC Research Notes.* 2021;14:98.
39. Li Y, Gao D, Liu J, Yang Z, Wen B, Chen L, et al. Prepubertal BMI, pubertal growth patterns, and long-term BMI: results from a longitudinal analysis in Chinese children and adolescents from 2005 to 2016. *Eur J Clin Nutr.* 2022;76:1432-9.
40. Marques M, Vieira F, Teles J, Baptista F. Growth and physical development of children at apparent risk of sarcopenia. *Pediatr Res.* 2025;97:843-50.
41. Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The 'muscle-bone unit' during the pubertal growth spurt. *Bone.* 2004;34:771-5.
42. Ká K, Rousseau MC, Lambert M, O'Loughlin J, Henderson M, Tremblay A, et al. Association between lean and fat mass and indicators of bone health in prepubertal caucasian children. *HRP.* 2013;80:154-62.
43. Sioen I, Lust E, De Henauw S, Moreno LA, Jiménez-Pavón D. Associations between body composition and bone health in children and adolescents: a systematic review. *Calcif Tissue Int.* 2016;99:557-77.
44. Schoenau E. From mechanostat theory to development of the «functional muscle-bone-unit». *J Musculoskelet Neuronal Interact.* 2005;5:232-8.
45. Wey HE, Binkley TL, Beare TM, Wey CL, Specker BL. Cross-sectional versus longitudinal associations of lean and fat mass with pQCT bone outcomes in children. *J Clin Endocrinol Metab.* 2011;96:106-14.
46. Schoenau E, Neu CM, Beck B, Manz F, Rauch F. Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. *J Bone Miner Res.* 2002;17:1095-101.
47. Matta PN, Baul TD, Loubeau K, Sikov J, Plasencia N, Sun Y, et al. Low sports participation is associated with withdrawn and depressed symptoms in urban, school-age children. *J Affect Disord.* 2021;280:24-9.
48. Bowden Davies KA, Pickles S, Sprung VS, Kemp GJ, Alam U, Moore DR, et al. Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. *Ther Adv Endocrinol Metab.* 2019;10:2042018819888824.
49. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care.* 2009;32:S157-63.
50. Atlan L, Cohen S, Shiran S, Sira LB, Pratt LT, Yerushalmy-Feler A. Sarcopenia is a predictor for adverse clinical outcome in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2021;72:883-8.
51. Rayar M, Webber CE, Nayiager T, Sala A, Barr RD. Sarcopenia in children with acute lymphoblastic leukemia. *J Pediatr Hematol Oncol.* 2013;35:98-102.
52. Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. *Int J Hematol.* 2018;107:486-9.
53. Van Aller C, Lara J, Stephan BC, Donini LM, Heymsfield S, Katzmarzyk PT, et al. Sarcopenic obesity and overall mortality: results from the application of novel models of body composition phenotypes to the National Health and Nutrition Examination Survey 1999-2004. *Clin Nutr.* 2019;38:264-70.
54. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. *NCHS Data Brief.* 2017;1-8.
55. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. *Clin Nutr.* 2012;31:583-601.
56. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. *Front Physiol.* 2013;4:371.
57. Trowbridge FL, Hiner CD, Robertson AD. Arm muscle indicators and creatinine excretion in children. *Am J Clin Nutr.* 1982;36:691-6.
58. Jacobs J, Jansen M, Janssen H, Rajjmann W, Van Alfen N, Pillen S. Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study. *Muscle Nerve.* 2013;47:856-63.
59. McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM. Skeletal muscle mass reference curves for children and adolescents. *Pediatr Obes.* 2014;9:249-59.
60. Lurz E, Patel H, Frimpong RG, Ricciuto A, Kehar M, Wales PW, et al. Sarcopenia in children with end-stage liver disease. *J Pediatr Gastroenterol Nutr.* 2018;66:222-6.
61. Ritz A, Lurz E, Berger M. Sarcopenia in children with solid organ tumors: an instrumental era. *Cells.* 2022;11:1278.
62. Mazahery H, von Hurst PR, McKinlay CJ, Cormack BE, Conlon CA. Air displacement plethysmography (pea pod) in full-term and pre-term infants: a comprehensive review of accuracy, reproducibility, and practical challenges. *Maternal Health Neonatol Perinatol.* 2018;4:12.
63. Clark RV, Walker AC, Miller RR, O'Connor-Semmes RL, Ravussin E, Cefalu WT. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. *J Appl Physiol.* 2018;124:1-9.
64. Wang Z, Heshka S, Pietrobelli A, Chen Z, Silva AM, Sardinha LB, et al. A new total body potassium method to estimate total body skeletal muscle mass in children. *J Nutr.* 2007;137:1988-91.
65. Arrowsmith FE, Allen JR, Gaskin KJ, Cruca MA, Clarke SL, Briody JN, et al. Reduced body protein in children with spastic quadriplegic cerebral palsy2. *Am J Clin Nutr.* 2006;83:613-8.
66. Curcio F, Ferro G, Basile C, Liguori I, Parrella P, Pirozzi F, et al. Biomarkers in sarcopenia: a multifactorial approach. *Exp Gerontol.* 2016;85:1-8.
67. Jones G, Trajanoska K, Santanasto AJ, Stringa N, Kuo CL, Atkins JL, et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. *Nat Commun.* 2021;12:654.
68. Gadher SJ, Jarkovska K, Kovarova H. Reproductive therapies and a need for potential biomarkers for prognostic and diagnostic screening of women desperate to conceive. *Expert Rev Proteomics.* 2009;6:591-3.
69. Valášková S, Gažová A, Vrbová P, Koller T, Šalíngova B, Adamičková A, et al. The severity of muscle performance deterioration in sarcopenia correlates with circulating muscle tissue-specific miRNAs. *Physiol Res.* 2021;70:S91-8.
70. Jatava SD, Thapar N, Broyles D, Dikici E, Daftarian P, Jiménez JJ, et al. Enhanced delivery of plasmid DNA to skeletal muscle cells using a DLC8-binding peptide and ASSLNIA-modified PAMAM dendrimer. *Mol Pharm.* 2019;16:2376-84.
71. Poussard S, Decossas M, Bihan OL, Mornet S, Naudin G, Lambert O. Internalization and fate of silica nanoparticles in C2C12 skeletal muscle cells:

evidence of a beneficial effect on myoblast fusion. *IJN*. 2015;10:1479-92.

72. Michiue K, Takayama K, Taniguchi A, Hayashi Y, Kogure K. Increasing skeletal muscle mass in mice by non-invasive intramuscular delivery of myostatin inhibitory peptide by iontophoresis. *Pharmaceuticals*. 2023;16:397.
73. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. *J Am Geriatr Soc*. 2010;58:1134-43.
74. Rong S, Wang L, Peng Z, Liao Y, Li D, Yang X, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? *J Cachexia Sarcopenia Muscle*. 2020;11:348-65.
75. Tian X, Pan M, Zhou M, Tang Q, Chen M, Hong W, et al. Mitochondria transplantation from stem cells for mitigating sarcopenia. *Aging Dis*. 2023;14:1700-13.

It should read:

19. Kwon EJ, Kim YJ. What is fetal programming? a lifetime health is under the control of in utero health. *Obstet Gynecol Sci*. 2017;60:506-19.
20. Costello PM, Rowleson A, Astaman NA, Anthony FE, Sayer AA, Cooper C, et al. Peri-implantation and late gestation maternal undernutrition differentially affect fetal sheep skeletal muscle development. *J Physiol*. 2008;586:2371-9.
21. Chomtho S, Wells JC, Williams JE, Lucas A, Fewtrell MS. Associations between birth weight and later body composition: evidence from the 4-component model. *Am J Clin Nutr*. 2008;88:1040-8.
22. Bielemann RM, Gigante DP, Horta BL. Birth weight, intrauterine growth restriction and nutritional status in childhood in relation to grip strength in adults: from the 1982 Pelotas (Brazil) birth cohort. *Nutrition*. 2016;32:228-35.
23. Dodds R, Denison HJ, Ntani G, Cooper R, Cooper C, Sayer AA, et al. Birth weight and muscle strength: a systematic review and meta-analysis. *J Nutr Health Aging*. 2012;16:609-15.
24. Narici MV, de Boer MD. Disuse of the musculo-skeletal system in space and on earth. *Eur J Appl Physiol*. 2011;111:403-20.
25. Jung HN, Jung CH, Hwang YC. Sarcopenia in youth. *Metabolism*. 2023;144:155557.
26. Benson AC, Torode ME, Fiatarone Singh MA. Muscular strength and cardiorespiratory fitness is associated with higher insulin sensitivity in children and adolescents. *Int J Pediatr Obes*. 2006;1:222-31.
27. Steene-Johannessen J, Anderssen SA, Kolle E, Andersen LB. Low muscle fitness is associated with metabolic risk in youth. *Med Sci Sports Exerc*. 2009;41:1361.
28. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic syndrome and sarcopenia. *Nutrients*. 2021;13:3519.
29. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. *Nutrients*. 2020;12:2401.
30. Phillips CM. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. *Ann N Y Acad Sci*. 2017;1391:85-100.
31. Rezende IF, Conceição-Machado ME, Souza VS, Santos EM dos, Silva LR. Sarcopenia in children and adolescents with chronic liver disease. *J Pediatr*. 2020;96:439-46.
32. Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. *Trends Endocrinol Metab*. 2016;27:335-47.
33. Zhang G, Wang D, Chen J, Tong M, Wang J, Chang J, et al. Association of sleep duration and prevalence of sarcopenia: a large cross-sectional study. *Prev Med Rep*. 2024;42:102741.
34. Rubio-Arias JA, Rodríguez-Fernández R, Andreu L, Martínez-Aranda LM, Martínez-Rodríguez A, Ramos-Campo DJ. Effect of sleep quality on the prevalence of sarcopenia in older adults: a systematic review with meta-analysis. *J Clin Med*. 2019;8:2156.
35. Liu C, Cheung W, Li J, Chow SK, Yu J, Wong SH, et al. Understanding the gut microbiota and sarcopenia: a systematic review. *J Cachexia Sarcopenia Muscle*. 2021;12:1393-407.
36. Uptodate Free. Measurement of growth in children. 2024. [cited 31 May 2024]. Available from: <https://pro.uptodatefree.ir/Show/5356>.
37. Beunen GP, Rogol AD, Malina RM. Indicators of biological maturation and secular changes in biological maturation. *Food Nutr Bull*. 2006;27:S244-56.
38. Rogol AD. Growth, body composition and hormonal axes in children and adolescents. *J Endocrinol Invest*. 2003;26:855-60.
39. Narchi H, Alblooshi A, Altunajji M, Alali N, Alshehhi L, Alshehhi H, et al. Prevalence of thinness and its effect on height velocity in schoolchildren. *BMC Research Notes*. 2021;14:98.
40. Li Y, Gao D, Liu J, Yang Z, Wen B, Chen L, et al. Prepubertal BMI, pubertal growth patterns, and long-term BMI: results from a longitudinal analysis in Chinese children and adolescents from 2005 to 2016. *Eur J Clin Nutr*. 2022;76:1432-9.
41. Marques M, Vieira F, Teles J, Baptista F. Growth and physical development of children at apparent risk of sarcopenia. *Pediatr Res*. 2025;97:843-50.
42. Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The 'muscle-bone unit' during the pubertal growth spurt. *Bone*. 2004;34:771-5.
43. Ká K, Rousseau MC, Lambert M, O'Loughlin J, Henderson M, Tremblay A, et al. Association between lean and fat mass and indicators of bone health in prepubertal caucasian children. *HRP*. 2013;80:154-62.
44. Sioen I, Lust E, De Henauw S, Moreno LA, Jiménez-Pavón D. Associations between body composition and bone health in children and adolescents: a systematic review. *Calcif Tissue Int*. 2016;99:557-77.
45. Schoenau E. From mechanostat theory to development of the «functional muscle-bone-unit». *J Musculoskelet Neuronal Interact*. 2005;5:232-8.
46. Wey HE, Binkley TL, Beare TM, Wey CL, Specker BL. Cross-sectional versus longitudinal associations of lean and fat mass with pQCT bone outcomes in children. *J Clin Endocrinol Metab*. 2011;96:106-14.
47. Schoenau E, Neu CM, Beck B, Manz F, Rauch F. Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. *J Bone Miner Res*. 2002;17:1095-101.
48. Matta PN, Baul TD, Loubeau K, Sikov J, Plasencia N, Sun Y, et al. Low sports participation is associated with withdrawn and depressed symptoms in urban, school-age children. *J Affect Disord*. 2021;280:24-9.
49. Bowden Davies KA, Pickles S, Sprung VS, Kemp GJ, Alam U, Moore DR, et al. Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. *Ther Adv Endocrinol Metab*. 2019;10:2042018819888824.
50. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care*. 2009;32:S157-63.
51. Atlan L, Cohen S, Shiran S, Sira LB, Pratt LT, Yerushalmy-Feler A. Sarcopenia is a predictor for adverse clinical outcome in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2021;72:883-8.
52. Rayar M, Webber CE, Nayjaeger T, Sala A, Barr RD. Sarcopenia in children with acute lymphoblastic leukemia. *J Pediatr Hematol Oncol*. 2013;35:98-102.
53. Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. *Int J Hematol*. 2018;107:486-9.
54. Van Aller C, Lara J, Stephan BC, Donini LM, Heymsfield S, Katzmarzyk PT, et al. Sarcopenic obesity and overall mortality: results from the application of novel models of body composition phenotypes to the National Health and Nutrition Examination Survey 1999-2004. *Clin Nutr*. 2019;38:264-70.
55. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. *NCHS Data Brief*. 2017;1-8.
56. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. *Clin Nutr*. 2012;31:583-601.
57. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. *Front Physiol*. 2013;4:371.
58. Trowbridge FL, Hiner CD, Robertson AD. Arm muscle indicators and creatinine excretion in children. *Am J Clin Nutr*. 1982;36:691-6.
59. Jacobs J, Jansen M, Janssen H, Rajjmann W, Van Alfen N, Pillen S. Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study. *Muscle Nerve*. 2013;47:856-63.

60. McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM. Skeletal muscle mass reference curves for children and adolescents. *Pediatr Obes.* 2014;9:249-59.
61. Lurz E, Patel H, Frimpong RG, Ricciuto A, Kehar M, Wales PW, et al. Sarcopenia in children with end-stage liver disease. *J Pediatr Gastroenterol Nutr.* 2018;66:222-6.
62. Ritz A, Lurz E, Berger M. Sarcopenia in children with solid organ tumors: an instrumental era. *Cells.* 2022;11:1278.
63. Mazahery H, von Hurst PR, McKinlay CJ, Cormack BE, Conlon CA. Air displacement plethysmography (pea pod) in full-term and pre-term infants: a comprehensive review of accuracy, reproducibility, and practical challenges. *Maternal Health Neonatol Perinatol.* 2018;4:12.
64. Clark RV, Walker AC, Miller RR, O'Connor-Semmes RL, Ravussin E, Cefalu WT. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. *J Appl Physiol.* 2018;124:1-9.
65. Wang Z, Heshka S, Pietrobelli A, Chen Z, Silva AM, Sardinha LB, et al. A new total body potassium method to estimate total body skeletal muscle mass in children. *J Nutr.* 2007;137:1988-91.
66. Arrowsmith FE, Allen JR, Gaskin KJ, Gruca MA, Clarke SL, Briody JN, et al. Reduced body protein in children with spastic quadriplegic cerebral palsy. *The American Journal of Clinical Nutrition.* 2006;83:613-8.
67. Jones G, Trajanoska K, Santanasto AJ, Stringa N, Kuo CL, Atkins JL, et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. *Nat Commun.* 2021;12:654.
68. Lin S, Ling M, Chen C, Cai X, Yang F, Fan Y. Screening potential diagnostic biomarkers for age-related sarcopenia in the elderly population by WGCNA and LASSO. *BioMed Res Int.* 2022;2022:7483911.
69. Valášková S, Gažová A, Vrbová P, Koller T, Šalingova B, Adamičková A, et al. The severity of muscle performance deterioration in sarcopenia correlates with circulating muscle tissue-specific miRNAs. *Physiol Res.* 2021;70:S91-8.
70. Jatava SD, Thapar N, Broyles D, Dikici E, Daftarian P, Jiménez JJ, et al. Enhanced delivery of plasmid DNA to skeletal muscle cells using a DLC8-binding peptide and ASSLNIA-modified PAMAM dendrimer. *Mol Pharm.* 2019;16:2376-84.
71. Poussard S, Decossas M, Bihan OL, Mornet S, Naudin G, Lambert O. Internalization and fate of silica nanoparticles in C2C12 skeletal muscle cells: evidence of a beneficial effect on myoblast fusion. *IJN.* 2015;10:1479-92.
72. Michiue K, Takayama K, Taniguchi A, Hayashi Y, Kogure K. Increasing skeletal muscle mass in mice by non-invasive intramuscular delivery of myostatin inhibitory peptide by iontophoresis. *Pharmaceuticals.* 2023;16:397.
73. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. *J Am Geriatr Soc.* 2010;58:1134-43.
74. Rong S, Wang L, Peng Z, Liao Y, Li D, Yang X, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? *J Cachexia Sarcopenia Muscle.* 2020;11:348-65.
75. Tian X, Pan M, Zhou M, Tang Q, Chen M, Hong W, et al. Mitochondria transplantation from stem cells for mitigating sarcopenia. *Aging Dis.* 2023;14:1700-13.
76. Najm A, Niculescu AG, Grumezescu AM, Beuran M. Emerging therapeutic strategies in sarcopenia: an updated review on pathogenesis and treatment advances. *Int J Mol Sci.* 2024;25:4300.

Original article:

<https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/23301/15785>

Updated article:

<https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/23301/15836>

Na página 801, no quinto parágrafo da coluna da esquerda, foi acrescentada uma referência e as referências seguintes foram renumeradas. Assim, onde se lê (a vermelho):

“Although initially focused on the elderly, sarcopenia has emerged as a growing concern among pediatric populations, particularly in children with chronic diseases. Recently, some studies have suggested that it may also be present in asymptomatic children.”¹⁷

Deverá ler-se (a negrito):

“Although initially focused on the elderly, sarcopenia has emerged as a growing concern among pediatric populations, particularly in children with chronic diseases. Recently, some studies have suggested that it may also be present in asymptomatic children.”¹⁸

Na página 805, no segundo parágrafo da secção '**FUTURE PERSPECTIVES**', a última frase foi removida (a vermelho). Assim, onde se lê:

“Due to the multifactorial nature of sarcopenia, there is an urgent need to develop validated biomarker panels for clinical use in both children and adults. Currently, inflammatory markers like TNF-alpha and IL-6 and others like testosterone, GH, creatinine, and carnitine are used.”⁶⁵

Deverá ler-se:

“Due to the multifactorial nature of sarcopenia, there is an urgent need to develop validated biomarker panels for clinical use in both children and adults.”

Na página 805, no terceiro parágrafo da secção '**FUTURE PERSPECTIVES**', onde se lê:

“Genomic studies have identified certain sequences linked to an increased risk of sarcopenia, such as the rs34415150 variant of HLA-DQA1, rs143384 of GDF5, and rs62102286 of DYM.⁶⁶ Additionally, in sarcopenic patients, genes like MT1X and ARHGAP36 have shown higher diagnostic precision compared to FAM171A1, GPCPD1, ZNF415, and RXRG,

indicating their potential as predictive markers for early screening.⁶⁷ Circulating microRNAs (e.g., microRNA-1, microRNA-29a, microRNA-29b) have also been observed in patients with reduced physical performance.⁶⁸

Deverá ler-se (a **negrito**):

“Genomic studies have identified certain sequences linked to an increased risk of sarcopenia **in older men and women**, such as the rs34415150 variant of HLA-DQA1, rs143384 of GDF5, and rs62102286 of DYM.⁶⁷ Additionally, in sarcopenic patients, genes like MT1X and ARHGAP36 have shown higher diagnostic precision compared to FAM171A1, GPCPD1, ZNF415, and RXRG, indicating their potential as predictive markers for early screening.⁶⁸ Circulating microRNAs (e.g., microRNA-1, microRNA-29a, microRNA-29b) have also been observed in **adult patients with reduced physical performance**.⁶⁹”

Na secção ‘**REFERENCES**’, todas as referências após a referência 18 foram renumeradas.

Assim, onde se lê:

19. Costello PM, Rowleson A, Astaman NA, Anthony FE, Sayer AA, Cooper C, et al. Peri-implantation and late gestation maternal undernutrition differentially affect fetal sheep skeletal muscle development. *J Physiol.* 2008;586:2371-9.
20. Chomtho S, Wells JC, Williams JE, Lucas A, Fewtrell MS. Associations between birth weight and later body composition: evidence from the 4-component model. *Am J Clin Nutr.* 2008;88:1040-8.
21. Bielemann RM, Gigante DP, Horta BL. Birth weight, intrauterine growth restriction and nutritional status in childhood in relation to grip strength in adults: from the 1982 Pelotas (Brazil) birth cohort. *Nutrition.* 2016;32:228-35.
22. Dodds R, Denison HJ, Ntani G, Cooper R, Cooper C, Sayer AA, et al. Birth weight and muscle strength: a systematic review and meta-analysis. *J Nutr Health Aging.* 2012;16:609-15.
23. Narici MV, de Boer MD. Disuse of the musculo-skeletal system in space and on earth. *Eur J Appl Physiol.* 2011;111:403-20.
24. Jung HN, Jung CH, Hwang YC. Sarcopenia in youth. *Metabolism.* 2023;144:155557.
25. Benson AC, Torode ME, Fiatarone Singh MA. Muscular strength and cardiorespiratory fitness is associated with higher insulin sensitivity in children and adolescents. *Int J Pediatr Obes.* 2006;1:222-31.
26. Steene-Johannessen J, Anderssen SA, Kolle E, Andersen LB. Low muscle fitness is associated with metabolic risk in youth. *Med Sci Sports Exerc.* 2009;41:1361.
27. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic syndrome and sarcopenia. *Nutrients.* 2021;13:3519.
28. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. *Nutrients.* 2020;12:2401.
29. Phillips CM. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. *Ann N Y Acad Sci.* 2017;1391:85-100.
30. Rezende IF, Conceição-Machado ME, Souza VS, Santos EM dos, Silva LR. Sarcopenia in children and adolescents with chronic liver disease. *J Pediatr.* 2020;96:439-46.
31. Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. *Trends Endocrinol Metab.* 2016;27:335-47.
32. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* 2010;39:412-23.
33. Rubio-Arias JA, Rodríguez-Fernández R, Andreu L, Martínez-Aranda LM, Martínez-Rodríguez A, Ramos-Campo DJ. Effect of sleep quality on the prevalence of sarcopenia in older adults: a systematic review with meta-analysis. *J Clin Med.* 2019;8:2156.
34. Liu C, Cheung W, Li J, Chow SK, Yu J, Wong SH, et al. Understanding the gut microbiota and sarcopenia: a systematic review. *J Cachexia Sarcopenia Muscle.* 2021;12:1393-407.
35. Uptodate Free. Measurement of growth in children. 2024. [cited 31 May 2024]. Available from: <https://pro.uptodatefree.ir/Show/5356>.
36. Beunen GP, Rogol AD, Malina RM. Indicators of biological maturation and secular changes in biological maturation. *Food Nutr Bull.* 2006;27:S244-56.
37. Rogol AD. Growth, body composition and hormonal axes in children and adolescents. *J Endocrinol Invest.* 2003;26:855-60.
38. Narchi H, Alblooshi A, Altunajji M, Alali N, Alshehhi L, Alshehhi H, et al. Prevalence of thinness and its effect on height velocity in schoolchildren. *BMC Research Notes.* 2021;14:98.
39. Li Y, Gao D, Liu J, Yang Z, Wen B, Chen L, et al. Prepubertal BMI, pubertal growth patterns, and long-term BMI: results from a longitudinal analysis in Chinese children and adolescents from 2005 to 2016. *Eur J Clin Nutr.* 2022;76:1432-9.
40. Marques M, Vieira F, Teles J, Baptista F. Growth and physical development of children at apparent risk of sarcopenia. *Pediatr Res.* 2025;97:843-50.
41. Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The ‘muscle-bone unit’ during the pubertal growth spurt. *Bone.* 2004;34:771-5.
42. Kâ K, Rousseau MC, Lambert M, O’Loughlin J, Henderson M, Tremblay A, et al. Association between lean and fat mass and indicators of bone health in prepubertal caucasian children. *HRP.* 2013;80:154-62.
43. Sioen I, Lust E, De Henauw S, Moreno LA, Jiménez-Pavón D. Associations between body composition and bone health in children and adolescents: a systematic review. *Calcif Tissue Int.* 2016;99:557-77.
44. Schoenau E. From mechanostat theory to development of the «functional muscle-bone-unit». *J Musculoskelet Neuronal Interact.* 2005;5:232-8.
45. Wey HE, Binkley TL, Beare TM, Wey CL, Specker BL. Cross-sectional versus longitudinal associations of lean and fat mass with pQCT bone outcomes in children. *J Clin Endocrinol Metab.* 2011;96:106-14.
46. Schoenau E, Neu CM, Beck B, Manz F, Rauch F. Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. *J Bone Miner Res.* 2002;17:1095-101.
47. Matta PN, Baul TD, Loubeau K, Sikov J, Plasencia N, Sun Y, et al. Low sports participation is associated with withdrawn and depressed symptoms in urban, school-age children. *J Affect Disord.* 2021;280:24-9.
48. Bowden Davies KA, Pickles S, Sprung VS, Kemp GJ, Alam U, Moore DR, et al. Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. *Ther Adv Endocrinol Metab.* 2019;10:2042018819888824.
49. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care.* 2009;32:S157-63.
50. Atlan L, Cohen S, Shiran S, Sira LB, Pratt LT, Yerushalmy-Feler A. Sarcopenia is a predictor for adverse clinical outcome in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2021;72:883-8.
51. Rayar M, Webber CE, Nayiager T, Sala A, Barr RD. Sarcopenia in children with acute lymphoblastic leukemia. *J Pediatr Hematol Oncol.* 2013;35:98-102.
52. Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. *Int J Hematol.* 2018;107:486-9.
53. Van Aller C, Lara J, Stephan BC, Donini LM, Heymsfield S, Katzmarzyk PT, et al. Sarcopenic obesity and overall mortality: results from the application of novel models of body composition phenotypes to the National Health and Nutrition Examination Survey 1999-2004. *Clin Nutr.* 2019;38:264-70.
54. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. *NCHS Data Brief.* 2017;1-8.

55. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. *Clin Nutr.* 2012;31:583-601.
56. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. *Front Physiol.* 2013;4:371.
57. Trowbridge FL, Hiner CD, Robertson AD. Arm muscle indicators and creatinine excretion in children. *Am J Clin Nutr.* 1982;36:691-6.
58. Jacobs J, Jansen M, Janssen H, Rajimann W, Van Alfen N, Pillen S. Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study. *Muscle Nerve.* 2013;47:856-63.
59. McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM. Skeletal muscle mass reference curves for children and adolescents. *Pediatr Obes.* 2014;9:249-59.
60. Lurz E, Patel H, Frimpong RG, Ricciuto A, Kehar M, Wales PW, et al. Sarcopenia in children with end-stage liver disease. *J Pediatr Gastroenterol Nutr.* 2018;66:222-6.
61. Ritz A, Lurz E, Berger M. Sarcopenia in children with solid organ tumors: an instrumental era. *Cells.* 2022;11:1278.
62. Mazahery H, von Hurst PR, McKinlay CJ, Cormack BE, Conlon CA. Air displacement plethysmography (pea pod) in full-term and pre-term infants: a comprehensive review of accuracy, reproducibility, and practical challenges. *Maternal Health Neonatol Perinatol.* 2018;4:12.
63. Clark RV, Walker AC, Miller RR, O'Connor-Semmes RL, Ravussin E, Cefalu WT. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. *J Appl Physiol.* 2018;124:1-9.
64. Wang Z, Heshka S, Pietrobelli A, Chen Z, Silva AM, Sardinha LB, et al. A new total body potassium method to estimate total body skeletal muscle mass in children. *J Nutr.* 2007;137:1988-91.
65. Arrowsmith FE, Allen JR, Gaskin KJ, Gruca MA, Clarke SL, Briody JN, et al. Reduced body protein in children with spastic quadriplegic cerebral palsy2. *Am J Clin Nutr.* 2006;83:613-8.
66. Curcio F, Ferro G, Basile C, Liguori I, Parrella P, Pirozzi F, et al. Biomarkers in sarcopenia: a multifactorial approach. *Exp Gerontol.* 2016;85:1-8.
67. Jones G, Trajanoska K, Santanasto AJ, Stringa N, Kuo CL, Atkins JL, et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. *Nat Commun.* 2021;12:654.
68. Gadher SJ, Jarkovska K, Kovarova H. Reproductive therapies and a need for potential biomarkers for prognostic and diagnostic screening of women desperate to conceive. *Expert Rev Proteomics.* 2009;6:591-3.
69. Valášková S, Gažová A, Vrbová P, Koller T, Šalingova B, Adamičková A, et al. The severity of muscle performance deterioration in sarcopenia correlates with circulating muscle tissue-specific miRNAs. *Physiol Res.* 2021;70:S91-8.
70. Jatava SD, Thapar N, Broyles D, Dikici E, Daftarian P, Jiménez JJ, et al. Enhanced delivery of plasmid DNA to skeletal muscle cells using a DLC8-binding peptide and ASSLNIA-modified PAMAM dendrimer. *Mol Pharm.* 2019;16:2376-84.
71. Poussard S, Decossas M, Bihan OL, Mornet S, Naudin G, Lambert O. Internalization and fate of silica nanoparticles in C2C12 skeletal muscle cells: evidence of beneficial effect on myoblast fusion. *IJN.* 2015;10:1479-92.
72. Michiue K, Takayama K, Taniguchi A, Hayashi Y, Kogure K. Increasing skeletal muscle mass in mice by non-invasive intramuscular delivery of myostatin inhibitory peptide by iontophoresis. *Pharmaceuticals.* 2023;16:397.
73. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. *J Am Geriatr Soc.* 2010;58:1134-43.
74. Rong S, Wang L, Peng Z, Liao Y, Li D, Yang X, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? *J Cachexia Sarcopenia Muscle.* 2020;11:348-65.
75. Tian X, Pan M, Zhou M, Tang Q, Chen M, Hong W, et al. Mitochondria transplantation from stem cells for mitigating sarcopenia. *Aging Dis.* 2023;14:1700-13.

Deverá ler-se:

19. Kwon EJ, Kim YJ. What is fetal programming? a lifetime health is under the control of in utero health. *Obstet Gynecol Sci.* 2017;60:506-19.
20. Costello PM, Rowleson A, Astaman NA, Anthony FE, Sayer AA, Cooper C, et al. Peri-implantation and late gestation maternal undernutrition differentially affect fetal sheep skeletal muscle development. *J Physiol.* 2008;586:2371-9.
21. Chomtho S, Wells JC, Williams JE, Lucas A, Fewtrell MS. Associations between birth weight and later body composition: evidence from the 4-component model. *Am J Clin Nutr.* 2008;88:1040-8.
22. Bielemann RM, Gigante DP, Horta BL. Birth weight, intrauterine growth restriction and nutritional status in childhood in relation to grip strength in adults: from the 1982 Pelotas (Brazil) birth cohort. *Nutrition.* 2016;32:228-35.
23. Dodds R, Denison HJ, Ntani G, Cooper R, Cooper C, Sayer AA, et al. Birth weight and muscle strength: a systematic review and meta-analysis. *J Nutr Health Aging.* 2012;16:609-15.
24. Narici MV, de Boer MD. Disuse of the musculo-skeletal system in space and on earth. *Eur J Appl Physiol.* 2011;111:403-20.
25. Jung HN, Jung CH, Hwang YC. Sarcopenia in youth. *Metabolism.* 2023;144:155557.
26. Benson AC, Torode ME, Fiatarone Singh MA. Muscular strength and cardiorespiratory fitness is associated with higher insulin sensitivity in children and adolescents. *Int J Pediatr Obes.* 2006;1:222-31.
27. Steene-Johannessen J, Anderssen SA, Kolle E, Andersen LB. Low muscle fitness is associated with metabolic risk in youth. *Med Sci Sports Exerc.* 2009;41:1361.
28. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic syndrome and sarcopenia. *Nutrients.* 2021;13:3519.
29. Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. *Nutrients.* 2020;12:2401.
30. Phillips CM. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. *Ann N Y Acad Sci.* 2017;1391:85-100.
31. Rezende IF, Conceição-Machado ME, Souza VS, Santos EM dos, Silva LR. Sarcopenia in children and adolescents with chronic liver disease. *J Pediatr.* 2020;96:439-46.
32. Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. *Trends Endocrinol Metab.* 2016;27:335-47.
33. Zhang G, Wang D, Chen J, Tong M, Wang J, Chang J, et al. Association of sleep duration and prevalence of sarcopenia: a large cross-sectional study. *Prev Med Rep.* 2024;42:102741.
34. Rubio-Arias JÁ, Rodríguez-Fernández R, Andreu L, Martínez-Aranda LM, Martínez-Rodríguez A, Ramos-Campo DJ. Effect of sleep quality on the prevalence of sarcopenia in older adults: a systematic review with meta-analysis. *J Clin Med.* 2019;8:2156.
35. Liu C, Cheung W, Li J, Chow SK, Yu J, Wong SH, et al. Understanding the gut microbiota and sarcopenia: a systematic review. *J Cachexia Sarcopenia Muscle.* 2021;12:1393-407.
36. Uptodate Free. Measurement of growth in children. 2024. [cited 31 May 2024]. Available from: <https://pro.uptodatefree.ir/Show/5356>.
37. Beunen GP, Rogol AD, Malina RM. Indicators of biological maturation and secular changes in biological maturation. *Food Nutr Bull.* 2006;27:S244-56.
38. Rogol AD. Growth, body composition and hormonal axes in children and adolescents. *J Endocrinol Invest.* 2003;26:855-60.
39. Narchi H, Alblooshi A, Altunajji M, Alali N, Alshehhi L, Alshehhi H, et al. Prevalence of thinness and its effect on height velocity in schoolchildren. *BMC Research Notes.* 2021;14:98.
40. Li Y, Gao D, Liu J, Yang Z, Wen B, Chen L, et al. Prepubertal BMI, pubertal growth patterns, and long-term BMI: results from a longitudinal analysis in Chinese children and adolescents from 2005 to 2016. *Eur J Clin Nutr.* 2022;76:1432-9.
41. Marques M, Vieira F, Teles J, Baptista F. Growth and physical development of children at apparent risk of sarcopenia. *Pediatr Res.* 2025;97:843-50.

42. Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The 'muscle-bone unit' during the pubertal growth spurt. *Bone*. 2004;34:771-5.
43. Kâ K, Rousseau MC, Lambert M, O'Loughlin J, Henderson M, Tremblay A, et al. Association between lean and fat mass and indicators of bone health in prepubertal caucasian children. *HRP*. 2013;80:154-62.
44. Sioen I, Lust E, De Henauw S, Moreno LA, Jiménez-Pavón D. Associations between body composition and bone health in children and adolescents: a systematic review. *Calcif Tissue Int*. 2016;99:557-77.
45. Schoenau E. From mechanostat theory to development of the «functional muscle-bone-unit». *J Musculoskelet Neuronal Interact*. 2005;5:232-8.
46. Wey HE, Binkley TL, Beare TM, Wey CL, Specker BL. Cross-sectional versus longitudinal associations of lean and fat mass with pQCT bone outcomes in children. *J Clin Endocrinol Metab*. 2011;96:106-14.
47. Schoenau E, Neu CM, Beck B, Manz F, Rauch F. Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. *J Bone Miner Res*. 2002;17:1095-101.
48. Matta PN, Baul TD, Loubeau K, Sikov J, Plasencia N, Sun Y, et al. Low sports participation is associated with withdrawn and depressed symptoms in urban, school-age children. *J Affect Disord*. 2021;280:24-9.
49. Bowden Davies KA, Pickles S, Sprung VS, Kemp GJ, Alam U, Moore DR, et al. Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. *Ther Adv Endocrinol Metab*. 2019;10:2042018819888824.
50. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care*. 2009;32:S157-63.
51. Atlan L, Cohen S, Shiran S, Sira LB, Pratt LT, Yerushalmy-Feler A. Sarcopenia is a predictor for adverse clinical outcome in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2021;72:883-8.
52. Rayar M, Webber CE, Nayiager T, Sala A, Barr RD. Sarcopenia in children with acute lymphoblastic leukemia. *J Pediatr Hematol Oncol*. 2013;35:98-102.
53. Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. *Int J Hematol*. 2018;107:486-9.
54. Van Aller C, Lara J, Stephan BC, Donini LM, Heymsfield S, Katzmarzyk PT, et al. Sarcopenic obesity and overall mortality: results from the application of novel models of body composition phenotypes to the National Health and Nutrition Examination Survey 1999-2004. *Clin Nutr*. 2019;38:264-70.
55. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. *NCHS Data Brief*. 2017;1-8.
56. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. *Clin Nutr*. 2012;31:583-601.
57. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. *Front Physiol*. 2013;4:371.
58. Trowbridge FL, Hiner CD, Robertson AD. Arm muscle indicators and creatinine excretion in children. *Am J Clin Nutr*. 1982;36:691-6.
59. Jacobs J, Jansen M, Janssen H, Rajimann W, Van Alfen N, Pillen S. Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study. *Muscle Nerve*. 2013;47:856-63.
60. McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM. Skeletal muscle mass reference curves for children and adolescents. *Pediatr Obes*. 2014;9:249-59.
61. Lurz E, Patel H, Frimpong RG, Ricciuto A, Kehar M, Wales PW, et al. Sarcopenia in children with end-stage liver disease. *J Pediatr Gastroenterol Nutr*. 2018;66:222-6.
62. Ritz A, Lurz E, Berger M. Sarcopenia in children with solid organ tumors: an instrumental era. *Cells*. 2022;11:1278.
63. Mazahery H, von Hurst PR, McKinlay CJ, Cormack BE, Conlon CA. Air displacement plethysmography (pea pod) in full-term and pre-term infants: a comprehensive review of accuracy, reproducibility, and practical challenges. *Maternal Health Neonatol Perinatol*. 2018;4:12.
64. Clark RV, Walker AC, Miller RR, O'Connor-Semmes RL, Ravussin E, Cefalu WT. Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. *J Appl Physiol*. 2018;124:1-9.
65. Wang Z, Heshka S, Pietrobelli A, Chen Z, Silva AM, Sardinha LB, et al. A new total body potassium method to estimate total body skeletal muscle mass in children. *J Nutr*. 2007;137:1988-91.
66. Arrowsmith FE, Allen JR, Gaskin KJ, Gruca MA, Clarke SL, Briody JN, et al. Reduced body protein in children with spastic quadriplegic cerebral palsy2. *The American Journal of Clinical Nutrition*. 2006;83:613-8.
67. Jones G, Trajanoska K, Santanasto AJ, Stringa N, Kuo CL, Atkins JL, et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. *Nat Commun*. 2021;12:654.
68. Lin S, Ling M, Chen C, Cai X, Yang F, Fan Y. Screening potential diagnostic biomarkers for age-related sarcopenia in the elderly population by WGCNA and LASSO. *BioMed Res Int*. 2022;2022:7483911.
69. Valášková S, Gažová A, Vrbová P, Koller T, Šalingsová B, Adamičková A, et al. The severity of muscle performance deterioration in sarcopenia correlates with circulating muscle tissue-specific miRNAs. *Physiol Res*. 2021;70:S91-8.
70. Jatava SD, Thapar N, Broyles D, Dikici E, Daftarian P, Jiménez JJ, et al. Enhanced delivery of plasmid DNA to skeletal muscle cells using a DLC8-binding peptide and ASSLNIA-modified PAMAM dendrimer. *Mol Pharm*. 2019;16:2376-84.
71. Poussard S, Decossas M, Bihan OL, Mornet S, Naudin G, Lambert O. Internalization and fate of silica nanoparticles in C2C12 skeletal muscle cells: evidence of a beneficial effect on myoblast fusion. *IJN*. 2015;10:1479-92.
72. Michiue K, Takayama K, Taniguchi A, Hayashi Y, Kogure K. Increasing skeletal muscle mass in mice by non-invasive intramuscular delivery of myostatin inhibitory peptide by iontophoresis. *Pharmaceuticals*. 2023;16:397.
73. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. *J Am Geriatr Soc*. 2010;58:1134-43.
74. Rong S, Wang L, Peng Z, Liao Y, Li D, Yang X, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? *J Cachexia Sarcopenia Muscle*. 2020;11:348-65.
75. Tian X, Pan M, Zhou M, Tang Q, Chen M, Hong W, et al. Mitochondria transplantation from stem cells for mitigating sarcopenia. *Aging Dis*. 2023;14:1700-13.
76. Najm A, Niculescu AG, Grumezescu AM, Beuran M. Emerging therapeutic strategies in sarcopenia: an updated review on pathogenesis and treatment advances. *Int J Mol Sci*. 2024;25:4300.

Artigo original:

<https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/23301/15785>

Artigo corrigido:

<https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/23301/15836>



<https://doi.org/10.20344/amp.24225>